Maiwei Biotech (688062.SH) disclosed its 2023 annual report. The company achieved revenue of 128 million during the reporting period...
According to Zhitong Finance App News, Maiwei Biotech (688062.SH) disclosed its 2023 annual report. During the reporting period, the company achieved revenue of 128 million yuan, an increase of 361.03%; net profit loss to mother of 1,053 million yuan, an increase over the previous year; loss after deducting non-net profit of 1.06 billion yuan, a large year-on-year loss; and basic earnings per share - 2.64 yuan.
The company's revenue during the reporting period increased by 100.1074 million yuan over the same period last year, up 361.03% year-on-year, mainly due to the 9MW3011 project reaching an exclusive license agreement with the US DISC MEDICINE, INC., and receiving a non-refundable down payment of $10 million from it. At the same time, Miley Shu confirmed revenue from sales of new products. 2. The net loss attributable to shareholders of listed companies during the reporting period and net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss increased by 98.1981,000 yuan and 93.1013 million yuan respectively over the same period of the previous year. This is mainly due to the fact that the company continued to invest a large amount of money in clinical trials of the products under development. Many varieties under development were in the critical registration clinical research stage, and the company's R&D expenses were higher, and sales expenses related to commercialization increased further with the launch of new products.
By the end of the reporting period, although the company's products Junmaikang and Milishu had been approved for marketing in March 2022 and March 2023 respectively, the company had not made a profit and had accumulated uncovered losses. The main reason was that Junmaikang and Milishu had a short time to go public, and the company, as an innovative biomedical company, had maintained high R&D investment since its establishment. As of the disclosure date of the report, the company has 14 varieties in clinical or marketing stages, including 10 innovative drugs and 4 biosimilar drugs, covering various treatment fields such as autoimmunity, oncology, metabolism, ophthalmology, and infections. Among them, 3 varieties have already been marketed, 1 variety in the marketing license review stage, 3 varieties in the critical phase III clinical registration stage, and 7 other varieties in different clinical stages. During the reporting period, the company invested 835.7818 million yuan in R&D, an increase of 10.17% over the same period last year.